BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/11/2021 11:07:20 AM | Browse: 414 | Download: 682
 |
Received |
|
2020-12-21 15:28 |
|
Peer-Review Started |
|
2020-12-21 15:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-01-17 06:10 |
|
Revised |
|
2021-01-25 14:32 |
|
Second Decision |
|
2021-03-15 12:59 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-03-16 04:19 |
|
Articles in Press |
|
2021-03-16 04:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-03-23 22:42 |
|
Typeset the Manuscript |
|
2021-04-12 14:21 |
|
Publish the Manuscript Online |
|
2021-05-11 11:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Min Fei, Xiang-Qiong Wen, Zhao-Lan Yu, Ting Kang, Wei-Hua Wu and San-Tao Ou |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
San-Tao Ou, MD, PhD, Chief Doctor, Professor, Department of Nephrology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. ousantao@163.com |
| Key Words |
Chronic kidney disease; Renal anemia; Erythropoiesis-stimulating agents; Erythropoiesis-stimulating agent resistance; Roxadustat; Case report |
| Core Tip |
Anemia is a common complication of chronic kidney disease, often in combination with increased morbidity and mortality. Treatment of anemia in advanced chronic kidney disease includes iron replacement and administration of erythropoiesis-stimulating agents (ESAs). However, anemia remains undertreated because of concerns about the safety of ESAs. Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) that stimulates erythropoiesis and regulates iron metabolism. We present a case in which Roxadustat was used for the treatment of a blood transfusion-dependent maintenance hemodialysis patient. This case highlights that increasing HIF activity with small-molecule HIF-PHIs such as Roxadustat is an innovative therapeutic approach for anemia. |
| Publish Date |
2021-05-11 11:07 |
| Citation |
Fei M, Wen XQ, Yu ZL, Kang T, Wu WH, Ou ST. Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. World J Clin Cases 2021; 9(15): 3680-3688 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i15/3680.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i15.3680 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
